Drugs / Lercanidipine
Lercanidipine
also known as
Cardiovasc · Lercanidipine hcl · Lercanidipine hydrochloride · Lercanidipino · Lercanil · REC-15/2375 · Zanidip
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01093807 | Mar 2010 → Mar 2011 | essential hypertension | RECORDATI GROUP | Completed | No outcome recorded |
| Phase 2 | NCT01122251 | Dec 2009 → May 2010 | essential hypertension | LG Life Sciences | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01211314 | Jan → Dec 2011 | hypertensive disorder | Meir Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT01180413 | Dec 2010 → Apr 2012 | essential hypertension | Aarhus University Hospital | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07020104 | Jan 2025 → Dec 2039 expected | chronic kidney disease | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| — | NCT00424801 | Jan 2007 → Dec 2008 | coronary microvascular disorder, essential hypertension | University of Aarhus | Terminated | No outcome recorded |
| — | NCT00160498 | May 2004 → Aug 2005 | hypertensive disorder | UCB Pharma | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 3 | NCT01928628 Comparator | May 2012 → Apr 2013 | essential hypertension | LG Life Sciences | Completed | Met primary |
| Phase 4 | NCT01520285 Comparator | Dec 2011 → Mar 2013 | essential hypertension | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 4 | NCT02594410 Background | Sep 2011 → Mar 2014 | hypertensive disorder | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00564057 Comparator | Sep 2007 → Sep 2009 | HIV infectious disease, hypertensive disorder | University of Insubria | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-03-15 | Lee's Pharmaceutical Limited | RECORDATI AND LEESPHARM ANNOUNCE PARTNERSHIP FOR ZANIDIP® IN CHINA leespharm.com ↗ |
| 2009-12-31 | Lee's Pharmaceutical Limited | Distribution Agreement signed to market Lercanidipine tablets in Hong Kong and Macau leespharm.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lercanidipine | “Lercanidipine hydrochloride (10mg/tablet)once per day” NCT01520285 ↗ |
| Known as | Cardiovasc | ChEMBL registry synonym — accepted as the source's own label CHEMBL250270 ↗ |
| Known as | Lercanidipine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL250270 ↗ |
| Known as | Lercanidipine hydrochloride | “Lercanidipine hydrochloride tablets (Zanidip®)” NCT01520285 ↗ |
| Known as | Lercanidipino | ChEMBL registry synonym — accepted as the source's own label CHEMBL250270 ↗ |
| Known as | Lercanil | ChEMBL registry synonym — accepted as the source's own label CHEMBL250270 ↗ |
| Known as | REC-15/2375 | ChEMBL registry synonym — accepted as the source's own label CHEMBL250270 ↗ |
| Known as | Zanidip | “Lercanidipine hydrochloride tablets (Zanidip®)” NCT01520285 ↗ |
| Action | Inhibit | “calcium channel blocker (lercanidipine)” NCT00564057 ↗ |
| Modality | Small molecule | — CHEMBL250270 ↗ |
| Route | Oral | “Lercanidipine 10 mg and 20 mg Once Daily p. o. in Hypertensive Subjects” NCT00160498 ↗ |